Follow
← Back
Medicines · Interactions

Dabigatran — interactions

Other medicines, foods and herbal products can change how Dabigatran works. Everything on this page comes from Dabigatran's own FDA-approved label — the same source as the main guide.

← Back to the full Dabigatran guide

⚠ Caution: • P-gp inducers: Avoid coadministration with dabigatran etexilate capsules • P-gp inhibitors in adult patients with CrCl 30 to 50 mL/min: Reduce dosage or avoid • P-gp inhibitors in adult patients with CrCl <30 mL/min: Not recommended

Medicines named in Dabigatran's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Reduction of Risk of Stroke and Systemic

Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided . P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran .

Treatment and Reduction

In the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Avoid use of dabigatran etexilate and P-gp inhibitors in patients with CrCl <50 mL/min .

Prophylaxis of Deep Vein Thrombosis and Pulmonary

Embolism in Adult Patients Following Hip Replacement Surgery In patients with CrCl ≥50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of dabigatran and the P-gp inhibitor by several hours.

Treatment and Reduction in Risk of Recurrence

Of VTE in Pediatric Patients The concomitant use of dabigatran etexilate capsules with P-gp inhibitors has not been studied in pediatric patients but may increase exposure to dabigatran .

Dabigatran's label names 5 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Dabigatran's label have interaction pages of their own:

Read the full interactions section from Dabigatran's label

• P-gp inducers: Avoid coadministration with dabigatran etexilate capsules • P-gp inhibitors in adult patients with CrCl 30 to 50 mL/min: Reduce dosage or avoid • P-gp inhibitors in adult patients with CrCl <30 mL/min: Not recommended

7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided . P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran . Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30 to 50 mL/min), reduce the dosage of dabigatran etexilate to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dosage adjustment of dabigatran etexilate. These results should not be extrapolated to other P-gp inhibitors . The concomitant use of dabigatran etexilate and P-gp inhibitors in patients with severe renal impairment (CrCl 15 to 30 mL/min) should be avoided .

7.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Avoid use of dabigatran etexilate and P-gp inhibitors in patients with CrCl <50 mL/min .

7.3 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery In patients with CrCl ≥50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of dabigatran and the P-gp inhibitor by several hours. The concomitant use of dabigatran etexilate and P-gp inhibitors in patients with CrCl <50 mL/min should be avoided .

7.4 Treatment and Reduction in Risk of Recurrence of VTE in Pediatric Patients The concomitant use of dabigatran etexilate capsules with P-gp inhibitors has not been studied in pediatric patients but may increase exposure to dabigatran .

Dabigatran guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 20 Nov 2025) · NepalDoc medicine catalog · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Dabigatran's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.